Cellens

Decision/Risk Analysis · Boston, MA · Founded 2019 · Privately Held (backing)

Developer of a cell surface scanning platform designed to assist oncologists in performing noninvasive detection of bladder cancer. Cellens is based in Boston, MA and was founded in 2019. It was valued at $19.4 million at its early-stage round in Aug 2025, the last priced event on record. It has raised $7.5 million across 3 recorded rounds; the latest was a $6.4 million early-stage round in Aug 2025.

PMV mark · valuation
$19.4M
Oct 2026
Priced at
its early-stage round
Aug 2025
Total raised
$7.5M
Last round
Early Stage VC
Aug 2025
What is Cellens worth?
$19.4MPrivateMarketView mark · Oct 2026

Valued at $19.4M at its early-stage round, Aug 2025. Nothing has traded since.

Free account
More of Cellens with a free account
  • ·The complete investor list: 19 names
  • ·Watch Cellens: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Valuation timeline

0 priced rounds · 32 daily marks since · Sep 2026 – Oct 2026
▮▮
Markrounds hold their value until the next priced eventMark, today
log scale
Post-money values unlock with a free account.Unlock the axis

Membership and data by Private Market View

Cellens funding history

3 rounds
DateRoundRaisedPost-money
Aug 2025Early Stage VC$6.4M▮
Sep 2024Accelerator/Incubator—▮
Apr 2022Debt$585K▮
Unlock post-money valuations

Membership and data by Private Market View

Cellens valuation

Cellens was valued at $19.4 million at its early-stage round in Aug 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has Cellens raised?

Cellens has raised $7.5 million across 3 recorded rounds since 2022. The largest was a $6.4 million early-stage round in Aug 2025.

Cellens has filed 2 Form Ds with the SEC since 2022, most recently in Nov 2025 ($6.4 million sold to 33 investors).

Comparable companies

Comparable decision/risk analysis names by valuation on PrivateMarketView: Anumana ($580 million), VideaHealth ($400 million) and Inductive Bio ($80 million).

How Cellens's valuation is determined

Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.

For Cellens, the most current credible signal sets the number and the older ones confirm it: a live secondary-market price first, then three or more recent prints, then institutional fund marks, and otherwise the last priced round, which never decays. The valuation is the last round’s post-money moved by the price change since that round, so no share count is assumed. Today it is set by its last priced round. Question about this number? Full methodology →

Frequently asked about Cellens

What is Cellens worth?
Cellens is valued at $19.4M as of Oct 2026. Valued at $19.4M at its early-stage round, Aug 2025. Nothing has traded since.
How much has Cellens raised?
Cellens has raised $7.5M in total funding across 3 recorded rounds.
When did Cellens last raise?
Cellens last raised in Aug 2025 (Early Stage VC), raising $6.4M.